Ionis Pharmaceuticals, Inc. (IONS) FY2026 Q2 P&L / Income Statement

Ionis Pharmaceuticals, Inc. (IONS) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue

267,949,000 US dollars

Cost of sales

2,739,000 US dollars

Gross profit (calculated)

265,210,000 US dollars

Operating expenses (calculated)

367,503,000 US dollars

Income (loss) from operations

negative 102,293,000 US dollars

Other income (expense), net (calculated)

negative 11,089,000 US dollars

Income (loss) before income tax benefit (expense)

negative 113,382,000 US dollars

Income tax benefit (expense)

1,264,000 US dollars

Net income (loss)

negative 114,646,000 US dollars

Collaborative Agreement Revenue

133,137,000 US dollars

DAWNZERA Sales, Net

26,565,000 US dollars

Other Commercial Revenue

11,526,000 US dollars

Other Royalties

6,036,000 US dollars

TRYNGOLZA Sales, Net

4,574,000 US dollars

WAINUA Joint Development Revenue

16,189,000 US dollars

Salanersen - Biogen Collaboration2017 Spinal Muscular Atrophy Member

45,000,000 US dollars

Sapablursen - Ono

20,000,000 US dollars

Undisclosed (calculated)

4,922,000 US dollars

Research, development and patent

217,107,000 US dollars

Selling, general and administrative

150,396,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.